Jubilant Ingrevia Limited management will participate in the Kotak Institutional Equity, India Corporate Day - Singapore 2026 on June 9 and June 10, 2026. The company disclosed this information in a regulatory filing submitted to the exchanges on May 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The event is scheduled to take place in Singapore and will be conducted in-person. The format of the meeting includes both group and one-on-one sessions with investors and analysts.

The company clarified that the discussions during the conference will be based on generally available information. It explicitly stated that the meetings are not related to any Unpublished Price Sensitive Information. The schedule for the event remains subject to change due to exigencies.

Event Details

Jubilant Ingrevia Limited has released the transcript of its investors' conference call for the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported its highest quarterly revenue in 14 quarters at ₹1,179 crore, a 12% year-on-year increase, driven by 10% volume growth. EBITDA stood at ₹172 crore, up 11% year-on-year, while PAT was ₹86 crore, rising 17% year-on-year. The Board has recommended a final dividend of ₹2.5 per share, taking the total FY26 dividend to ₹5 per share.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The submission was made by Deepanjali Gulati, Company Secretary of Jubilant Ingrevia .

Financial Performance

Management highlighted that Specialty Chemicals achieved its best quarterly revenue at ₹516 crore, with EBITDA margins maintained at 27% for the last six quarters. The Nutrition business reported segment revenue of ₹230 crore, up 21% year-on-year, with segment EBITDA growing 42% quarter-on-quarter. The company's net debt-to-EBITDA ratio improved to 0.99x.

Strategic Updates

Jubilant Ingrevia noted effective handling of the Middle East crisis with no production loss. The company completed the acquisition of Remidex Pharma to accelerate its Human Nutrition business and successfully commissioned the Bharuch CDMO plant. Management expects sequential growth in revenue and EBITDA starting from Q1 FY27, driven by Specialty Chemicals and Nutrition.

Key Details

The transcript can be accessed via the link provided on the company's website.